Interpace Biosciences appoints Christopher McCarthy as Principal Financial Officer

INTERPACE BIOSCIENCES, INC.

Christopher McCarthy, 31, appointed Principal Financial Officer effective April 21, 2023.
McCarthy had served as VP of Finance and Enterprise Systems since August 2022.
Prior roles at Interpace: Senior Director of Operations Finance (Aug 2020-Aug 2022) and Senior Financial Analyst (June 2019-Aug 2020).
Before Interpace, he was Senior Financial Systems Analyst at Simon & Schuster (Jan 2016-June 2019).
No family relationships or related party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher McCarthy

Principal Financial Officer

IDXG · INTERPACE BIOSCIENCES, INC.

Effective: 2023-04-21
Filed: April 25, 2023, 7:59 PM ET

On April 21, 2023, the Board of Directors of Interpace Biosciences, Inc. (the “Company”) appointed Christopher McCarthy, age 31, who has served as the Company’s Vice President of Finance and Enterprise Systems since August 2022, as Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher McCarthy was appointed as Principal Financial Officer at INTERPACE BIOSCIENCES, INC..

Action: appointed
Role: Principal Financial Officer

Exact text from the filing

On April 21, 2023, the Board of Directors of Interpace Biosciences, Inc. (the “Company”) appointed Christopher McCarthy, age 31, who has served as the Company’s Vice President of Finance and Enterprise Systems since August 2022, as Principal Financial Officer.

View on SEC.gov

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-013426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.